title: Preoperative radiotherapy for operable rectal cancer--is a lower dose to a reduced volume acceptable?
abstract: OBJECTIVE
  A retrospective audit was carried out to determine the rate of local recurrence (recurrent tumour within the lesser pelvis or the perineal wound) in 88 rectal cancer patients treated with 20 Gy/four fractions of adjuvant preoperative radiotherapy and curative surgery.
  
  
  METHODS
  All patients were followed-up by clinical examination with rigid sigmoidoscopy at 6 monthly intervals if the rectum was intact, and computed tomography of the pelvis at 1, 2 and 5 years after surgery. In total, 171 patients with rectal cancer were identified under the care of one surgeon over a period of 11 years from May 1992 to April 2003. We excluded patients with rectal cancer from preoperative adjuvant radiotherapy if they had evidence at presentation of distant metastases, if they had fixed rectal tumours, were treated by local excision and had previous radiotherapy to the pelvis. On this basis, only 88 were considered for preoperative radiotherapy and curative resection with a median follow-up of 5.16 years.
  
  
  RESULTS
  The 5-year survival by stage was Dukes A 96%, Dukes B 65% and Dukes C 36%. Overall, four patients (of 88) developed a recurrence within the lesser pelvis or the perineal wound, giving a local recurrence of 4.2% at 3 years (from a Kaplan-Meier graph).
  
  
  CONCLUSIONS
  This single-centre audit suggests that a lower dose of radiotherapy to a smaller volume provides an acceptable local recurrence rate that compares very favourably with the well-publicised Swedish and Dutch trials of 25 Gy/five fractions. It was not the intention of this audit to suggest that this dose should be widely adopted. However, given the long-term gastrointestinal morbidity and risk of second malignancies, we advise caution when formulating even more intensive radiotherapy and chemoradiotherapy regimens for rectal cancer.
authors.affiliation: Department of Clinical Oncology, Christie Hospital, Manchester, UK. mark.saunders@christie-tr.nwest.nhs.uk
authors.forename: M P
authors.initials: MP
authors.lastname: Saunders
authors.forename: H
authors.initials: H
authors.lastname: Alderson
authors.forename: A
authors.initials: A
authors.lastname: Chittalia
authors.forename: S
authors.initials: S
authors.lastname: Hughes
authors.forename: R D
authors.initials: RD
authors.lastname: James
authors.forename: G
authors.initials: G
authors.lastname: Armstrong
authors.forename: R
authors.initials: R
authors.lastname: Swindell
authors.forename: N A
authors.initials: NA
authors.lastname: Scott
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D011300:Preoperative Care; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D012004:Rectal Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D012189:Retrospective Studies